Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Soligenix Inc.
DescriptionOral beclomethasone 17,21-dipropionate (BDP)
Molecular Target Corticoid receptors
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I/II
Standard IndicationCrohn's disease
Indication DetailsTreat pediatric Crohn's disease (CD)
Regulatory Designation U.S. - Fast Track (Treat pediatric Crohn's disease (CD));
U.S. - Orphan Drug (Treat pediatric Crohn's disease (CD))

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today